- Vaccine produced by a partnership between a University of Oxford research institute, Vaccitech, and AstraZeneca, does not need to be stored at freezing temperatures.
- Cheaper and easier to produce than the high-efficacy vaccines produced by BioNTech-Pfizer and Moderna.
- The price of AstraZeneca’s shares dropped on the news, and an analysis from an investment bank concluded, “We believe that this product will never be licensed in the US.”
- A closer look at the the Oxford-AstraZeneca trials reveals some very shaky science.
- Cherry-picked the data
- Dosing issues
- Opaque planning and data analysis procedures
- Age group selection
https://www.wired.com/story/the-astrazeneca-covid-vaccine-data-isnt-up-to-snuff/